ClinicalTrials.gg
WithdrawnNCT06347055Updated Oct 9, 2026

NeuroControl of Nicotine Dependence

An interventional study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Nicotine Dependence, sponsored by University of Missouri-Columbia. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Missouri-Columbia · Not applicable, Interventional, and Basic science

How we know

Why this study was withdrawn
Funding
Updated Oct 9, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 799 studies in Tobacco Use Disorder with a site in United States — 75 open to participants now, 91 under way, 5 of them phase 3. Tobacco Use Disorder · United States.

Enrollment
701st of 736
0 · median 84
Started
2024
with 33 others
No phase
364 of 799
47 open now
Registered
734th of 799
by date

Among the 799 studies in Tobacco Use Disorder with a site in United States, this one is the 701st largest by enrollment of the 736 interventional ones that give a count, is one of 34 that started in 2024, is one of 364 with no phase, and was the 734th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

75 of the 799 studies in Tobacco Use Disorder with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 799 studies in Tobacco Use Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to examine the effects of continuous theta burst stimulation (cTBS) on different forms of cognitive control in adults who smoke cigarettes, and to determine if the location where cTBS is delivered may help smokers reduce or quit smoking. Participation in the study will take 3-weeks over 4 visits, with a total time commitment of approximately 12 hours.

03

Conditions studied

  • Nicotine Dependence

Keywords

  • Tobacco
  • Smoking
  • TMS
  • fMRI
  • Nicotine
  • Cognitive Control
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Nicotine Dependence as measured by: Smoke ≥ 8 cigarettes/day for ≥ 2 yrs, expired carbon monoxide (CO) concentration of ≥ 10 ppm, positive urine cotinine test and FTND score ≥ 3 Or ≥ 15 uses of electronic cigarette/day for ≥ 1 year, positive urine cotinine test, and PS-ECDI score ≥ 3
  2. English Fluency
  3. Functional Vision (with corrective lenses as needed)

Exclusion criteria

Exclusion Criteria:

  1. Use of psychotropic and antiepileptic medications in the last month
  2. Presence of an untreated illness or serious medical condition
  3. History of major neurological illness
  4. to TMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for >15 min., implanted electronic device, metal in the head) or MRI.
  5. Any use of substances that lower seizure threshold.
  6. Current or past psychosis
  7. Electroconvulsive therapy in the past 6 months
  8. Unstable cardiac disease or hypertension, severe renal or liver insufficiency, or sleep apnea
  9. BAC greater than 0.0.
  10. Positive urine pregnancy test
  11. Any other concern that in the investigator's opinion would impact participant safety, study instruction compliance, or confound the interpretation of the study results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    cTBS to Ventrolateral Prefrontal Cortex

    Continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. cTBS will be applied to the ventrolateral prefrontal cortex.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    cTBS to Dorsomedial Prefrontal Cortex

    Continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. cTBS will be applied to the dorsomedial prefrontal cortex.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Experimental
    cTBS to Vertex

    Continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. cTBS will be applied to the vertex.

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

Interventions

  • DeviceRepetitive Transcranial Magnetic Stimulation (rTMS)

    Continuous theta burst rTMS

    Also known as: cTBS

06

What researchers measure

Primary outcomes

  1. Acute effects of cTBS on cognitive control

    between-arm differences in neurocognitive task performance as measured by percent correct on an inhibitory control task and self reported craving on a regulation of craving task.

    Time frame: 1 hour after receiving cTBS

Secondary outcomes

  1. Exploratory: Acute effects of cTBS on fMRI brain response

    between-arm differences in whole brain fMRI BOLD functional connectivity. Neural network connectivity will be characterized using rZ values.

    Time frame: 1 hour after receiving cTBS

Other outcomes

  1. Safety and Tolerability

    Safety and tolerability of cTBS administered to each cortical location, as measured by self reported side effects on a review of symptoms questionnaire.

    Time frame: 24 hours following receipt of cTBS

07

Study locations

1 site
  • Health Neuroscience Center
    Columbia, Missouri 65203, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Mar 2030, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Apr 4, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Mar 25, 2030
CompletionEst.
Apr 30, 2030
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn Funding
changed Oct 9, 2026
Enrollment
30 (estimated)→0 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Withdrawn
    Why stopped Funding
    Enrollment 30 (estimated)→0 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06347055
Responsible party
Brett Froeliger (Professor, University of Missouri-Columbia) — Principal investigator
First posted
Apr 4, 2024
Start date
Oct 1, 2024
Primary completion
Mar 25, 2030 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion